Rare Disease Drug Commercialization With Zevra Therapeutics' Neil McFarlane
About this episode
Neil McFarlane discusses the transition of Zevra Therapeutics into a focused rare disease company and the importance of patient advocacy and AI in identifying patients.
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Neil McFarlane, CEO at Zevra Therapeutics, talks about transitioning to a focused rare disease company through acquisitions, and building out a commercial organization. Neil explains the importance of working with rare disease patient advocacy groups, using AI to analyze electronic health records and claims data to identify and diagnose patients with Niemann-Pick disease type C, and adap...
People in this episode
Host: Ben Comer
Guest: Neil McFarlane
Topics covered
- rare disease
- drug commercialization
- patient advocacy
- AI in healthcare
- health records analysis
Keywords
- rare disease
- drug commercialization
- Zevra Therapeutics
- Niemann-Pick disease
- AI
- patient advocacy
- health records
Mentioned in this episode
Organizations: Zevra Therapeutics
Products: Niemann-Pick disease type C
More episodes of Business Of Biotech
- The Editors' Roundtable: A Midyear Look At The 2026 Life Sciences Industry
- Derisking CNS Drug Development With Tortugas Neuroscience's Jeff Jonas, M.D.
- Scaling Manufacturing For Personalized Cell Therapies With Cellino's Marinna Madrid, Ph.D.
- Building A New Antibody Discovery Platform With Infinimmune's Wyatt McDonnell, Ph.D.
Explore listener stats, chart rankings, contacts and more on the Business Of Biotech podcast page.